Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,565 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT07536061RecruitingPhase 1
Testing SRP-1005 in early-stage Huntington's disease
This first-in-human study tests whether SRP-1005, a new drug, is safe and tolerable in people with early Huntington's disease. The drug is designed to reduce levels of a harmful protein in the brain that causes Huntington's symptoms.
Westmead, New South WalesAges 21–70 - NCT07059962Recruiting
Sensor-based congestion alert for peritoneal dialysis
This study tests a new sensor system that can predict fluid overload (congestion) in people on peritoneal dialysis. It may help you and your care team spot problems early so you can avoid hospital visits.
Victorville, CaliforniaAges 21 years+ - NCT07190209RecruitingPhase 3
Testing lunsekimig for COPD with frequent flare-ups
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
Chandler, ArizonaAges 40–80 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Irvine, CaliforniaAges 50 years+ - NCT07683325RecruitingPhase 2
Study of ontunisertib for fibrostenosing Crohn's disease
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
Bradenton, FloridaAges 18 years+ - NCT07404865RecruitingPhase 3
Telitacicept for active primary Sjögren's disease
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
Chandler, ArizonaAges 18–75 - NCT06214507Recruiting
Danon disease natural history study
This study follows people with Danon disease over time to better understand how the condition progresses. It may help guide future treatments.
Phoenix, ArizonaAges 8 years+ - NCT07661056RecruitingPhase 3
Investigational drug for treating graves' disease overactive thyroid
This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.
Tucson, ArizonaAges 18–70 - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT07753603RecruitingPhase 3
Linsitinib for active moderate to severe thyroid eye disease
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
Glendale, ArizonaAges 18 years+ - NCT00344331Recruiting
Testing blood and MRI markers for Niemann-Pick type C
This study measures biochemical (blood/biologic) markers and may use clinical evaluation and MRI to better understand Niemann-Pick disease type C. It could help improve how the condition is tracked and understood over time.
Bethesda, MarylandAges 1 day–120 years - NCT01168271Recruiting
Study malaria risk factors in pregnancy and young children
This study looks at why some people get malaria during pregnancy, and how young children’s bodies respond early in life. It may help researchers understand who is more likely to get malaria and why, which could guide future prevention and care.
BamakoAges 1 day–45 years - NCT06455800Recruiting
Severe lung disease in childhood
This study looks at severe lung disease in children. It may help doctors better understand and treat these conditions.
OdenseAges 1 day–18 years - NCT06638944RecruitingPhase 2
Wearable feedback device for swallowing therapy in stroke or Parkinson's
This study tests a wearable device that provides feedback to help improve swallowing in people with stroke or Parkinson's disease. It may help make swallowing therapy more effective by showing real-time progress during exercises.
Champaign, IllinoisAges 50–90 - NCT01193075Recruiting
Tracking the course of charcot-marie-tooth disease over time
This study follows people with certain types of Charcot-Marie-Tooth disease (CMT), a genetic nerve disorder, over time to understand how the condition progresses. It also includes healthy volunteers as controls, and no experimental treatments are given.
Los Angeles, CaliforniaAges Any age - NCT07238556Recruiting
Digital exercise program for cardiovascular risk
This study tests a new digital tool that helps clinicians prescribe personalized exercise plans to patients with cardiovascular risk factors like high blood pressure, diabetes, or obesity. Participation involves using the tool and following an exercise plan for a few months to see if it improves health.
Farmington, ConnecticutAges 18–64 - NCT06297291Recruiting
Blood pressure study after kidney nerve treatment
This study looks at how well a procedure that uses sound waves to calm kidney nerves (renal denervation) lowers blood pressure over time. It may help people whose blood pressure stays high despite taking medication.
Long Beach, CaliforniaAges 18 years+ - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT07378644RecruitingPhase 2/Phase 3
Testing SKY-0515 for Huntington's disease
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
Englewood, ColoradoAges 25 years+ - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Chandler, ArizonaAges 55–90 - NCT05152394RecruitingPhase 1
Testing cord stem cell exosome treatment for Parkinson’s safety
This Phase 1 study tests whether a treatment made from donated umbilical cord “exosomes” is safe in people with Parkinson’s disease. It mainly looks at side effects and safety, and could help guide future treatments if it proves tolerable.
Naples, FloridaAges Any age - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Homewood, AlabamaAges 55–90 - NCT07587658RecruitingPhase 4
Dupilumab after a severe COPD flare-up
This study tests whether adding the drug dupilumab to usual hospital care for a severe COPD flare-up helps patients recover better than usual care alone. It is for adults with a specific type of inflammation in their blood, and may reduce the chance of future flare-ups.
Mullica Hill, New JerseyAges 40 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,565 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.